The biotech industry can be volatile even for relatively large companies. Amgen (NASDAQ: AMGN), one of the more prominent ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

New studies in JACC highlight improvements in cardiac structure and function among CABG patients, as well as changes in ...

The alternative is for either investors or regulators to find out during the drug's approval process ... data included in ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

The stock's early-sessions lows when it was down more than 10% had put it on track to be Amgen's (AMGN) worst one-day percentage fall since a 13.4% drop on Oct. 27, 2000, according to Dow Jones Market ...

Mizuho Securities analyst Salim Syed has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday.Don't Miss our Black ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...